If you have HPV-positive throat cancer that's advanced or you have a significant smoking history, you're at higher risk of the cancer returning after treatment. Doctors wanted to see if adding a drug called nivolumab (an immunotherapy) before the usual combination of chemotherapy and radiation could help. In this trial, 41 patients received two infusions of nivolumab first, while 20 patients went straight to the standard treatment.
The main goal was to see if patients could complete the entire new treatment plan on schedule. The strategy was not considered feasible because 4 out of the 41 patients in the nivolumab group could not receive the full planned dose of their chemotherapy drug, cisplatin, due to side effects. In fact, all of the most severe (grade 4-5) side effects during treatment happened in the group that got nivolumab first, affecting seven patients.
After about three years of follow-up, the cancer came back less often in the group that received nivolumab. The estimated relapse rate at two years was 7.3% for that group, compared to 15.0% for the group that had standard treatment alone. While this difference looks promising, the researchers caution that it's an early finding from a small study and needs to be confirmed in larger trials. The takeaway is that this approach might reduce relapse but comes with a real trade-off in increased side effects.